In Silico and in Vitro Assessment of OATP1B1 Inhibition in Drug Discovery.
暂无分享,去创建一个
Matthew L. Danielson | Matthew L Danielson | Prashant V Desai | Thomas J. Raub | G. Sawada | Thomas J Raub | P. Desai | Geri A Sawada
[1] K. Maeda. Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. , 2015, Biological & pharmaceutical bulletin.
[2] Richard Svensson,et al. In Vitro and In Silico Strategies to Identify OATP1B1 Inhibitors and Predict Clinical Drug–Drug Interactions , 2011, Pharmaceutical Research.
[3] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[4] Michal Vieth,et al. Structure-guided expansion of kinase fragment libraries driven by support vector machine models. , 2010, Biochimica et biophysica acta.
[5] Ian A. Watson,et al. Integration of in silico and in vitro tools for scaffold optimization during drug discovery: predicting P-glycoprotein efflux. , 2013, Molecular pharmaceutics.
[6] Kim E. Garbison,et al. The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies , 2006, Journal of biomolecular screening.
[7] Yuichi Sugiyama,et al. Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A , 2003, Journal of Pharmacology and Experimental Therapeutics.
[8] K. Giacomini,et al. SLC transporters as therapeutic targets: emerging opportunities , 2015, Nature Reviews Drug Discovery.
[9] Kwang-Hwi Cho,et al. Computational classification models for predicting the interaction of compounds with hepatic organic ion importers. , 2015, Drug metabolism and pharmacokinetics.
[10] P. Neuvonen,et al. Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.
[11] The Development, Characterization, and Application of an OATP1B1 Inhibition Assay in Drug Discovery , 2012, Drug Metabolism and Disposition.
[12] Kazuya Maeda,et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. , 2013, Biopharmaceutics & drug disposition.
[13] M. Niemi,et al. Cyclosporine A Increases Plasma Concentrations and Effects of Repaglinide , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[14] Robert P. Sheridan,et al. Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling , 2003, J. Chem. Inf. Comput. Sci..
[15] Sanjay K. Nigam,et al. What do drug transporters really do? , 2014, Nature Reviews Drug Discovery.
[16] A. Mathiowetz,et al. Medicinal chemistry design principles for liver targeting through OATP transporters. , 2013, Current topics in medicinal chemistry.
[17] Lei Zhang,et al. Comparing Various In Vitro Prediction Criteria to Assess the Potential of a New Molecular Entity to Inhibit Organic Anion Transporting Polypeptide 1B1 , 2016, Journal of clinical pharmacology.
[18] Matthew L. Danielson,et al. In Silico ADME Techniques Used in Early-Phase Drug Discovery , 2017 .
[19] Stefan Brenner,et al. Identification of Novel Inhibitors of Organic Anion Transporting Polypeptides 1B1 and 1B3 (OATP1B1 and OATP1B3) Using a Consensus Vote of Six Classification Models , 2015, Molecular pharmaceutics.
[20] P. Selzer,et al. Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.
[21] J. Dearden,et al. QSAR modeling: where have you been? Where are you going to? , 2014, Journal of medicinal chemistry.
[22] B. Feng,et al. Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion , 2012, Drug Metabolism and Disposition.
[23] Maykel Pérez González,et al. Variable selection methods in QSAR: an overview. , 2008, Current topics in medicinal chemistry.
[24] G. V. van Westen,et al. Structure-Based Identification of OATP1B1/3 Inhibitors , 2013, Molecular Pharmacology.
[25] S. Ekins,et al. Comparative Pharmacophore Modeling of Organic Anion Transporting Polypeptides: A Meta-Analysis of Rat Oatp1a1 and Human OATP1B1 , 2005, Journal of Pharmacology and Experimental Therapeutics.
[26] T. Ghafourian,et al. Effect of OATP-binding on the prediction of biliary excretion , 2017, Xenobiotica; the fate of foreign compounds in biological systems.
[27] J. Venhorst,et al. Generation of Bayesian prediction models for OATP-mediated drug-drug interactions based on inhibition screen of OATP1B1, OATP1B1∗15 and OATP1B3. , 2015, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[28] Wei Zhou,et al. High-Dimensional Descriptor Selection and Computational QSAR Modeling for Antitumor Activity of ARC-111 Analogues Based on Support Vector Regression (SVR) , 2012, International journal of molecular sciences.
[29] B. Stieger,et al. Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil , 2007, Drug Metabolism and Disposition.
[30] S. Winiwarter,et al. Modeling Organic Anion-Transporting Polypeptide 1B1 Inhibition to Elucidate Interaction Risks in Early Drug Design. , 2016, Journal of pharmaceutical sciences.
[31] Ulf Norinder,et al. Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions , 2012, Journal of medicinal chemistry.
[32] Paul D. Martin,et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine , 2004, Clinical pharmacology and therapeutics.
[33] Yuichi Sugiyama,et al. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. , 2006, Pharmacology & therapeutics.